Digital pathology
Paige
Digital pathology AI applications for cancer pathology, including Paige Prostate.
Last updated: May 25, 2026
Back to directoryLumea medical AI product profile
Digital pathology platform connecting specimen workflow, whole-slide viewing, case management, AI integrations, and specialty diagnostic workflows.
Digital pathology
Best fit
Specialty pathology groups that want one operational layer for digital diagnosis, AI partner access, molecular testing, and lab workflow standardization.
- Primary use case
- Integrated digital pathology workflow with tissue-handling tools, FDA-cleared viewer, LIS-enabled case management, AI ecosystem access, and molecular test ordering
- Audience
- Urology, dermatology, gastroenterology, pathology, and outpatient diagnostic groups moving to digital pathology workflows
- Risk level
- High
- Pricing signal
- Enterprise pathology-lab pricing; request current module, viewer, LIS, AI partner, and service terms.
- Official sources
- 5 official sources
Compare within workflow: Digital pathology · comparison shortlist · source index
Regulatory, privacy, evidence, and workflow lens
product-specific source-backed lens: These product-specific signals summarize what the cited sources imply before treating Lumea as safe for a local clinical, operational, or research workflow.
| Regulatory / FDA | Separate Viewer+ primary-diagnosis claims from BxLink, AI marketplace tools, molecular-ordering workflows, and tissue-handling products; each module and partner algorithm needs its own intended-use review. |
|---|---|
| Privacy | Review HIPAA/HITECH documentation, endpoint controls for remote pathologists, encryption, authentication, image storage, AI partner integrations, LIS data flow, retention, and customer-contract terms. |
| Evidence | Check viewer validation, scanner compatibility, specialty workflow claims, AI partner evidence, molecular-ordering performance, and local turnaround-time or diagnostic-quality metrics. |
| Workflow | Best evaluated as a full pathology operating workflow where specimen handling, slide viewing, AI review, molecular ordering, and final signout are mapped together. |
Where Lumea fits
Lumea describes an integrated digital pathology workflow spanning tissue handling, Viewer+, BxLink, AI partner integrations, molecular testing, and specialty workflows; its public materials say Viewer+ is FDA-cleared for primary clinical diagnosis with whole-slide images while BxLink is not approved by FDA for digital primary diagnosis.
Not for: Diagnostic use without module-specific regulatory review, scanner validation, local lab controls, and pathologist signout responsibility.
What to verify before using Lumea
- Which Lumea component is in scope: Viewer+, BxLink, tissue-handling tools, specialty workflow, AI marketplace, or molecular ordering.
- FDA-cleared, CE-marked, CAP-guideline, RUO, or non-diagnostic status for the exact viewer, LIS, AI partner, and geography.
- Scanner compatibility, LIS integration, remote-access security, endpoint controls, image retention, and AI partner data flow.
- How pathologists review AI outputs, molecular orders, case routing, exceptions, and final report responsibility.
Source links
Use these links to confirm current claims, terms, regulatory status, pricing, and deployment requirements.
- lumeadigital.com
- lumeadigital.com / pathology
- lumeadigital.com / bxlink
- lumeadigital.com / fda-cleared-digital-pathology-viewer
- lumeadigital.com / privacy-policy
Related medical AI products
Digital pathology
Digital pathology
PathAI
AI-enabled digital pathology platform with image management and algorithm access.
Digital pathology
Ibex Medical Analytics
Clinical-grade AI pathology platform for cancer diagnostics and pathology workflow support.
Digital pathology
Proscia
Concentriq digital pathology platform that supports diagnostic, research, and AI-enabled pathology workflows.